公开(公告)号：US10086010B2

公开(公告)日：2018-10-02

申请号：US15126777

申请日：2015-03-17

Applicant: STC.UNM ,  Hiroshi Ide

Inventor： Yoshihiro Matsumoto ,  Alan Edward Tomkinson ,  Hiroshi Ide

IPC: A01N43/04 ,  A61K31/70 ,  A61K31/7072 ,  A61K31/513 ,  A61P35/00 ,  A61K45/06 ,  A61K31/7064 ,  A61K31/706 ,  A61K31/7068

Abstract: In one embodiment, the invention provides a method of treating a subject who suffers from a neoplasm (including a cancer such as a radiotherapeutic-resistant cancer) by administering to the subject a therapeutically effective amount of (a) 5-formyl-2′-deoxyuridine (fdU or foUdR) or a 5-formyl-2′-deoxyuridine derivative, optionally in combination with 5-hydroxy-2′-deoxyuridine (hUdR); and (b) at least one composition selected from the group consisting of either 5-fluorouracil (5-FU), a 5-FU prodrug (e.g. 5-fluoro-2′-deoxyuridine (FdU)) or 5-FU metabolite. In a preferred embodiment, a subject who suffers from colorectal cancer (CRC) or metastatic colorectal cancer (mCRC) is treated with a therapeutically-effective amount of fdU and either 5-FU or the 5-FU prodrug 5-fluoro-2′-deoxyuridine (FdU). Related pharmaceutical compositions are also provided.

公开(公告)号：US20180125875A1

公开(公告)日：2018-05-10

申请号：US15126777

申请日：2015-03-17

Applicant: Hiroshi Ide ,  STC.UNM

Inventor： Yoshihiro Matsumoto ,  Alan Edward Tomkinson ,  Hiroshi Ide

IPC: A61K31/7072 ,  A61K31/513 ,  A61K45/06 ,  A61P35/00

CPC classification number: A61K31/7072 ,  A61K31/337 ,  A61K31/4184 ,  A61K31/44 ,  A61K31/454 ,  A61K31/4745 ,  A61K31/495 ,  A61K31/513 ,  A61K31/519 ,  A61K31/55 ,  A61K31/555 ,  A61K31/675 ,  A61K31/706 ,  A61K31/7064 ,  A61K31/7068 ,  A61K33/24 ,  A61K38/14 ,  A61K45/06 ,  A61K2300/00 ,  A61P35/00

Abstract: In one embodiment, the invention provides a method of treating a subject who suffers from a neoplasm (including a cancer such as a radiotherapeutic-resistant cancer) by administering to the subject a therapeutically effective amount of (a) 5-formyl-2′-deoxyuridine (fdU or foUdR) or a 5-formyl-2′-deoxyuridine derivative, optionally in combination with 5-hydroxy-2′-deoxyuridine (hUdR); and (b) at least one composition selected from the group consisting of either 5-fluorouracil (5-FU), a 5-FU prodrug (e.g. 5-fluoro-2′-deoxyuridine (FdU)) or 5-FU metabolite. In a preferred embodiment, a subject who suffers from colorectal cancer (CRC) or metastatic colorectal cancer (mCRC) is treated with a therapeutically-effective amount of fdU and either 5-FU or the 5-FU prodrug 5-fluoro-2′-deoxyuridine (FdU). Related pharmaceutical compositions are also provided.

公开(公告)号：US09623008B2

公开(公告)日：2017-04-18

申请号：US14793878

申请日：2015-07-08

Applicant: STC.UNM ,  UNIVERSITY OF MARYLAND, BALTIMORE

Inventor： Alan Edward Tomkinson ,  Feyruz Rassool

IPC: A61K31/415 ,  C40B40/06 ,  A61K31/4184 ,  A61K31/165 ,  C12Q1/68 ,  G06F19/20 ,  A61K31/00

CPC classification number: A61K31/4184 ,  A61K31/00 ,  A61K31/165 ,  A61K45/06 ,  C12Q1/00 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/57407 ,  G01N33/57434 ,  G06F19/00 ,  G06F19/20 ,  G06F19/3456 ,  Y02A90/26 ,  A61K2300/00

Abstract: In one embodiment, the invention provides a method of treating a subject suffering from a breast cancer tumor which is non-responsive or intrinsically resistant to anti-estrogen therapy comprising administering a therapeutically effective amount of an inhibitor of alternative (ALT) non-homologous end joining (NHEJ) factor to the subject.In another embodiment the invention provides a method of treating a subject who suffers from a pancreatic cancer which is non-responsive to chemotherapy and/or radiation comprising co-administering a therapeutically effective amount of PARP1 inhibitor and a DNA ligase IIIα inhibitor to the subject. Related diagnostic methods, nucleic acid arrays, devices and kits are also provided.

公开(公告)号：US09132120B1

公开(公告)日：2015-09-15

申请号：US13783785

申请日：2013-03-04

Applicant: STC.UNM ,  University of Maryland, Baltimore

Inventor： Alan Edward Tomkinson ,  Feyruz Rassool

IPC: A61K31/4184 ,  C40B40/06 ,  A61K31/165

CPC classification number: A61K31/4184 ,  A61K31/00 ,  A61K31/165 ,  A61K45/06 ,  C12Q1/00 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/57407 ,  G01N33/57434 ,  G06F19/00 ,  G06F19/20 ,  G06F19/3456 ,  Y02A90/26 ,  A61K2300/00

Abstract: In one embodiment, the invention provides a method of treating a subject suffering from a breast cancer tumor which is non-responsive or intrinsically resistant to anti-estrogen therapy comprising administering a therapeutically effective amount of an inhibitor of alternative (ALT) non-homologous end joining (NHEJ) factor to the subject.In another embodiment the invention provides a method of treating a subject who suffers from a pancreatic cancer which is non-responsive to chemotherapy and/or radiation comprising co-administering a therapeutically effective amount of PARP1 inhibitor and a DNA ligase IIIα inhibitor to the subject. Related diagnostic methods, nucleic acid arrays, devices and kits are also provided.

Abstract translation: 在一个实施方案中，本发明提供了治疗患有对抗雌激素疗法无反应或本质上抗性的乳腺癌肿瘤的受试者的方法，其包括施用治疗有效量的替代（ALT）非同源末端的抑制剂 加入（NHEJ）因素。 在另一个实施方案中，本发明提供了治疗患有对化学疗法和/或放射线无反应的胰腺癌的受试者的方法，包括向受试者共同施用治疗有效量的PARP1抑制剂和DNA连接酶IIIα抑制剂。 还提供了相关的诊断方法，核酸阵列，装置和试剂盒。

公开(公告)号：US20160051517A1

公开(公告)日：2016-02-25

申请号：US14793878

申请日：2015-07-08

Applicant: STC.UNM ,  UNIVERSITY OF MARYLAND, BALTIMORE

Inventor： Alan Edward Tomkinson ,  Feyruz Rassool

IPC: A61K31/4184 ,  C12Q1/68 ,  G06F19/20 ,  A61K31/165

CPC classification number: A61K31/4184 ,  A61K31/00 ,  A61K31/165 ,  A61K45/06 ,  C12Q1/00 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/57407 ,  G01N33/57434 ,  G06F19/00 ,  G06F19/20 ,  G06F19/3456 ,  Y02A90/26 ,  A61K2300/00

Abstract: In one embodiment, the invention provides a method of treating a subject suffering from a breast cancer tumor which is non-responsive or intrinsically resistant to anti-estrogen therapy comprising administering a therapeutically effective amount of an inhibitor of alternative (ALT) non-homologous end joining (NHEJ) factor to the subject.In another embodiment the invention provides a method of treating a subject who suffers from a pancreatic cancer which is non-responsive to chemotherapy and/or radiation comprising co-administering a therapeutically effective amount of PARP1 inhibitor and a DNA ligase IIIα inhibitor to the subject. Related diagnostic methods, nucleic acid arrays, devices and kits are also provided.

Abstract translation: 在一个实施方案中，本发明提供了治疗患有对抗雌激素疗法无反应或本质上抗性的乳腺癌肿瘤的受试者的方法，其包括施用治疗有效量的替代（ALT）非同源末端的抑制剂 加入（NHEJ）因素。 在另一个实施方案中，本发明提供了治疗患有对化学疗法和/或放射线无反应的胰腺癌的受试者的方法，包括向受试者共同施用治疗有效量的PARP1抑制剂和DNA连接酶IIIα抑制剂。 还提供了相关的诊断方法，核酸阵列，装置和试剂盒。